Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

GSK and University of Nottingham Collaborate to Create Centre of Excellence for Sustainable Chemistry

Published: Friday, April 27, 2012
Last Updated: Friday, April 27, 2012
Bookmark and Share
Innovative carbon neutral laboratory to be established on University Campus.

GlaxoSmithKline (GSK) and The University of Nottingham have formalized a collaboration to establish a new laboratory to accommodate a Centre of Excellence for sustainable chemistry, and to construct an innovative carbon neutral sustainable chemistry laboratory.

This agreement represents progress on GSK’s ‘green chemistry’ commitment first announced in 2010.

The GlaxoSmithKline Carbon Neutral Laboratory for Sustainable Chemistry will be based on the University’s Jubilee Campus and its construction is being supported by a £12m grant from GSK.

The laboratory will be a Centre of Excellence for sustainable chemistry and will focus on research that is of particular relevance to the pharmaceutical industry and which complements established expertise at the University of Nottingham.

It will also deliver advanced undergraduate teaching and outreach to the wider scientific community to embed sustainable chemistry principles in the next generation of scientists.

The Centre of Excellence will serve as a global hub to catalyze new collaborations with other institutions and industry partners and will bring together leading UK academics, postgraduate and postdoctoral researchers and GSK chemists, developing expertise in sustainable chemical synthesis.

The focus on sustainability will be reflected in the building itself, which will incorporate the latest technologies to allow it to be carbon-neutral over its lifetime.

The laboratory will be built from natural materials and energy required to run the laboratory will be met by renewable sources such as solar power and sustainable biofuel.

Excess energy created by the building will provide enough carbon credits over 25 years to pay back the carbon used in its construction.

Sir Andrew Witty, CEO of GSK said: “The carbon neutral laboratory will help affirm the UK as a global hub for the future of the life-sciences industry. Our vision is that the science researched within the laboratory will be as iconic as the building itself. This is an opportunity to invest further in science in the UK, re-think how we approach the drug discovery process and play a role in contributing to environmental stewardship.”

Professor David Greenaway, Vice-Chancellor of The University of Nottingham, said: “This development will be transformational in several dimensions: the built form will break new ground in sustainable construction; the Centre of Excellence will shape the future of drug discovery; and innovation in training and development will accelerate the translation of discovery to application. This is all tremendously exciting and will underpin a unique partnership between GSK and the University of Nottingham.”

Today’s announcement builds on GSK’s environmental strategy announced in 2011, with an objective that the company’s operations will become carbon neutral by 2050.

Adopting sustainable chemistries from the start of the drug discovery process will help to reduce the impact of both the discovery and subsequent manufacturing of drugs on the environment, whilst optimizing the use of increasingly scarce natural resources.

GSK will also fund a research programme to gather information on aspects of the carbon neutral laboratory that could be transferred into the existing GSK estate to increase efficiency, reduce energy consumption and carbon emissions.

Minister for Universities and Science David Willetts said: “This new laboratory is an excellent example of collaboration between universities and industry. It shows how businesses can benefit from the knowledge and expertise of our world leading research base and will help keep us at the very forefront of life sciences.”

GSK’s donation is a key contribution to the University’s fundraising campaign, a five-year drive to raise £150m, launched in October 2011. ‘Impact: The Nottingham Campaign’ focuses around the five themes of Sustainable Futures, Health & Wellbeing, Ingenuity, Nurturing Talent and the Nottingham Experience.

The University of Nottingham is renowned for its scientific excellence, with a broad portfolio of chemistry-based degree courses.

GSK has a number of existing relationships with the University including providing support through postgraduate chemistry studentships, delivering a medicinal chemistry module to third year undergraduate chemists and offering opportunities for fourth year MSci project students to participate in live GSK research programmes.

The University continues to provide GSK with high quality chemists for industrial placements, graduate and postgraduate roles.

Christopher Moody, Sir Jesse Boot Professor of Chemistry at University of Nottingham, said: “The carbon neutral laboratory is an outstanding opportunity to put in place an innovative new research training framework and develop an ethos for sustainable synthesis that will be unique in the UK. We will investigate new methods to address problems in synthetic chemistry, whilst building a greater awareness of the environmental impact of choice of solvents, reagents and procedures.”

Construction of the laboratory will begin in the spring of 2013 and it is expected to be completed during 2014.

It will be one of the first laboratory buildings designed to Building Research Establishment Environmental Assessment Method (BREEAM) ‘Outstanding’ standard, and will be located on the University’s Jubilee Campus - an exemplar of brownfield regeneration, with buildings that demonstrate best practice in renewable energy technologies and environmentally-friendly design.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More Than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

GSK’s Shingles Vaccine Candidate Shows High Efficacy
The vaccine candidate showed high efficacy against shingles and its complications in adults aged 70yrs+ in phase III study.
Tuesday, September 20, 2016
GSK Presents Positive Results From Phase III Study
GSK reports positive results from phase III FULFIL study of closed triple combination therapy FF/UMEC/VI versus Symbicort® Turbohaler® in COPD.
Friday, September 09, 2016
GSK, Verily establish Galvani Bioelectronics
Following a GSK, Verily agreement, Galvani Bioelectronics will be formed with £540M investment to advance bioelectronic medicines.
Tuesday, August 02, 2016
GSK Announces £275M UK Investment
GSK has announced £275 million of new manufacturing site investment to boost production and support product delivery.
Friday, July 29, 2016
GSK’s RA Trail Using Apple’s ResearchKit
GSK is the first pharmaceutical company to start a trail using Apple’s ResearchKit. They hope to gathering data on rheumatoid arthritis.
Wednesday, July 20, 2016
GSK, Zymeworks Collaborate
Focus on the research, development, and commercialization of novel Fc-engineered monoclonal and bi-specific antibody therapeutics which have been optimized for specific therapeutic effects.
Friday, December 04, 2015
GSK, Idera to Collaborate
Idera to collaborate with GSK to identify 3rd generation antisense molecules for treatment of renal disease.
Monday, November 30, 2015
GSK and Merck to Study Immunotherapy Combination as Potential Cancer Treatment
Phase I first-in-human study to evaluate GSK’s OX40 agonist GSK3174998 as monotherapy and in combination with Merck’s anti-PD-1 therapy, Keytruda® (pembrolizumab).
Friday, November 06, 2015
GSK, UNC-Chapel Hill Launch $20M HIV Partnership
This new collaboration will be focused on curing HIV through a jointly-owned new company and a research center.
Tuesday, May 12, 2015
GSK to Establish Global Vaccines R&D Centre in the US
New hub based in Rockville, MD expands GSK’s global vaccines R&D footprint.
Thursday, April 09, 2015
GSK Awarded Up to $200 Million by U.S. Government to Develop New Antibiotics
Funding will support development of drugs to fight antibiotic resistance and bioterrorism.
Friday, May 24, 2013
GSK Launches Discovery Fast Track Competition for Academic Researchers
Scientists in U.S., Canada challenged to submit groundbreaking research proposals for chance at collaborative partnership focused on drug discovery.
Wednesday, May 22, 2013
GSK and Impax Pharmaceuticals Terminate Their Collaboration on IPX066
Both Companies end collaboration for the development and commercialization of IPX066 outside the United States and Taiwan.
Tuesday, May 07, 2013
GSK and Impax Terminate Their Collaboration
The companies are terminating their collaboration for the development and commercialisation of IPX066 outside the United States and Taiwan.
Tuesday, April 30, 2013
FDA Approves GlaxoSmithKline’s Four-Strain Seasonal Influenza Vaccine for Use in the US
FLUARIX® QUADRIVALENT is for the immunisation of children (3+) and adults to help prevent disease caused by seasonal influenza (flu) virus subtypes A and type B contained in the vaccine.
Thursday, December 20, 2012
Scientific News
Point of Care Diagnostics - A Cautious Revolution
Advances in molecular biology, coupled with the miniaturization and improved sensitivity of assays and devices in general, have enabled a new wave of point-of-care (POC) or “bedside” diagnostics.
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
One Step Closer to Precision Medicine for Chronic Lung Disease Sufferers
A study led by University of North Carolina at Chapel Hill, and National Jewish Health, has provided evidence of links between SNPs and known COPD blood protein biomarkers.
Blood Pressure Drug May Boost Effectiveness of Lung Cancer Treatment
Researchers at Imperial College London have suggested that the blood pressure drug may make a type of lung cancer treatment more effective.
Insight into Eye Diseases
Scientists recreate zebrafish cell regeneration from retinal stem cells in mice.
New Discovery May Benefit Farmers Worldwide
Scientists have shown how a crop-microbe 'team' protect against fungal infection.
Antibodies Paving the Way to HIV Vaccine
Researchers uncover factors responsible for the formation of broadly neutralizing HIV antibodies in humans.
Designing Drugs with a Whole New Toolbox
Researchers develop methods to design small, targeted proteins with shapes not found in nature.
Protein Studies Discover Molecular Secrets
Two protein studies have mapped proteins that reveal the secrets to recycling carbon and healing cells.
Tapping Evolution to Improve Biotech Products
Researchers show how 'ancestral sequence reconstruction' can be used to guide engineering of a blood clotting protein.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!